Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on oncology therapeutics that completed its business combination with Brookline Capital Acquisition Corp. in 2022. The SPAC, sponsored by Brookline Capital Markets, held its initial public offering in 2021 and targeted the life sciences and biotechnology sector. The July 2022 Form 8-K filing, submitted to the SEC under accession number 0001193125-22-203697, reflects activity tied to the post-merger public entity operating within the oncology drug development space. Apexigen's pipeline centers on antibody-based cancer treatments designed to engage the immune system against tumor cells. Visit SpacDesk and sign up for full data, filings history, and deal analytics on Apexigen and hundreds of other SPAC transactions.